Novartis gets FDA priority review for heart failure medicine LCZ696
The company has submitted a new drug application (NDA) under the FDA’s fast track program and is based on results from the PARADIGM-HF trial, which is claimed to
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.